Prognostic Significance of ctDNA in HL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Prognostic Significance of ctDNA in HL — Stella

Home/Prognostic Cancer Model/

View on ClinicalTrials.gov

Recruiting

Back to Prognostic Cancer Model trials

Trial locations(5 sites)

Czechia

University Hospital Hradec Kralove, Hradec Králové

University Hospital Olomouc, Olomouc

University Hospital Kralovske Vinohrady, Prague

Charles University, Prague

General University Hospital, Prague

Key details

Sponsor

Interni hematologicka klinika FNKV

Collaborators

Charles University, Czech Republic, General University Hospital, Prague

Enrollment target

~500 participants

Started

January 2022

Primary completion

December 2023

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated February 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.